- Home
- NBBK vs BIOA Comparison
NBBK vs BIOA Comparison
Compare NBBK & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBBK | BIOA |
|---|---|---|
| Founded | 1892 | 2015 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 856.3M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | NBBK | BIOA |
|---|---|---|
| Price | $21.75 | $21.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $23.00 | ★ $40.50 |
| AVG Volume (30 Days) | 359.1K | ★ 601.6K |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 365.22 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $43.56 | N/A |
| Revenue Next Year | $31.58 | N/A |
| P/E Ratio | $18.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.09 | $2.88 |
| 52 Week High | $22.70 | $24.00 |
Technical Indicators
Market Signals| Indicator | NBBK | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 67.70 |
| Support Level | $21.10 | $18.62 |
| Resistance Level | $21.58 | $24.00 |
| Average True Range (ATR) | 0.57 | 1.43 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 18.59 | 78.10 |
Price Performance
Historical ComparisonAbout NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
About BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.